U.S. Markets closed

BioSig Technologies, Inc. (BSGM)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.8500+0.0500 (+1.79%)
At close: 4:00PM EDT
2.8600 +0.01 (0.35%)
After hours: 04:32PM EDT

BioSig Technologies, Inc.

54 Wilton Road
2nd Floor
Westport, CT 06880
United States
203 409 5444
http://www.biosig.com

Sector(s)Healthcare
IndustryMedical Devices
Full Time Employees49

Key Executives

NameTitlePayExercisedYear Born
Mr. Kenneth L. Londoner M.B.A., MBAFounder, CEO & Exec. Chairman1.2MN/A1968
Mr. Steven ChaussyChief Financial OfficerN/AN/A1954
Dr. Budimir S. Drakulic Ph.D.Chief ScientistN/AN/A1950
Ms. Lora MikolaitisVP of Admin.N/AN/A1973
Mr. Andrew Gornell BallouVP of Investor RelationsN/AN/AN/A
Mr. John M. KowalskiVP of SalesN/AN/AN/A
Mr. Olivier ChaudoirSr. Director of MarketingN/AN/AN/A
Ms. Brenda CastrodadDirector of HRN/AN/AN/A
Ms. Natasha DrapeauExec. VPN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation and ventricular tachycardia. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.

Corporate Governance

BioSig Technologies, Inc.’s ISS Governance QualityScore as of June 1, 2021 is 10. The pillar scores are Audit: 10; Board: 9; Shareholder Rights: 7; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.